AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32054150
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint blocker (ICB) therapy
Trial: 32055862
Drug: Diethylcarbamazine treatment
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine treatment
Trial: 32057467
Drug: Nivolumab 240mg
RxNorm normalized name: nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 240mg Q2W for 6 infusions and ipilimumab 1mg/kg Q6W for 2 infusions in neoadjuvant setting, followed by nivolumab 480mg Q4W for 9 infusions post-surgery.
Trial: 32058557
Drug: gFOLFIRINOX therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gFOLFIRINOX therapy (fluorouracil 2400 mg/m2 over 46 hours; oxaliplatin 85 mg/m2; irinotecan 180 mg/m2 for UGT1A1 genotype 6/6, 135 mg/m2 for 6/7, or 90 mg/m2 for 7/7; prophylactic peg-filgastrim 6 mg) for 4 cycles before and after surgery.
Trial: 32058557
Drug: gFOLFIRINOX therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gFOLFIRINOX therapy with trastuzumab for ERBB2-positive tumors.
Trial: 32058557
Drug: gFOLFIRINOX therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gFOLFIRINOX therapy (including trastuzumab for ERBB2-positive tumors)
Trial: 32058843
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) at recommended doses for expansion (5.4 or 6.4 mg/kg) administered intravenously once every 3 weeks
Trial: 32058843
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) at 6.4 mg/kg
Trial: 32059719
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (382 patients)
Trial: 32059719
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (589 patients, 388 RYGB and 201 SG)
Trial: 32059719
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (156 patients left the study without treatment)
Trial: 32060053
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously on day 1 and capecitabine 1000 mg/m²
Trial: 32060165
Drug: Intravenous or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous or intramuscular thiamine (100 mg daily for a minimum of 3 days)
Trial: 32061453
Drug: Single ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ketamine infusion (0.5 mg/kg)
Trial: 32061453
Drug: Repeated ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated ketamine infusions (0.5 mg/kg)
Trial: 32062041
Drug: Vedolizumab therapy
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab therapy
Trial: 32062172
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment for lesions with FFR (≤0.8) and CFR (<2.0)
Trial: 32062681
Drug: Lanreotide autogel/depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide autogel/depot (LAN) combined with peptide receptor radionuclide therapy (PRRT)
Trial: 32063492
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg/d) with ADT and RT (66 Gy)
Trial: 32063845
Drug: Mephedrone plus
RxNorm normalized name: Mephedrone
DrugBank: Mephedrone (DB13108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mephedrone plus alcohol (200 mg mephedrone + 0.8 g/kg alcohol)
Trial: 32063845
Drug: Mephedrone alone
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mephedrone alone (200 mg mephedrone + placebo alcohol)
Trial: 32063845
Drug: Alcohol alone
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol alone (placebo mephedrone + 0.8 g/kg ethanol)
Trial: 32064663
Drug: Digital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital treatment augmentation study
Trial: 32064766
Drug: ART drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART drug costs
Trial: 32065330
Drug: JNJ-4178 (adafosbuvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-4178 (adafosbuvir 800 mg QD, odalasvir 25 mg QD, simeprevir 75 mg QD) for 8 weeks (Cohort 1) or 12 weeks (Cohort 2)
Trial: 32065330
Drug: JNJ-4178 (adafosbuvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-4178 (adafosbuvir 800 mg QD, odalasvir 25 mg QD, simeprevir 75 mg QD)
Trial: 32065359
Drug: Rosuvastatin 5
RxNorm normalized name: rosuvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5 mg/ezetimibe 10 mg once daily
Trial: 32065631
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate/emtricitabine 300/200 mg daily for 14 days
Trial: 32066540
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg once daily, taken orally, until progression or unacceptable toxicity.
Trial: 32067048
Drug: DTaP-IPV-Hib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months later.
Trial: 32067679
Drug: Residual PIK3CA
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual PIK3CA mutations in plasma after chemotherapy
Trial: 32067683
Drug: chemotherapy-free regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy-free regimens matched to specific molecular alterations
Trial: 32067695
Drug: Optimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal treatment of underlying conditions
Trial: 32070310
Drug: CPAP oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP oxygen treatment
Trial: 32071055
Drug: LPV/r-4:1 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r-4:1 (1 month after treatment completion)
Trial: 32071418
Drug: Ruxolitinib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib therapy in acute srGVHD
Trial: 32071418
Drug: Ruxolitinib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib therapy in chronic srGVHD
Trial: 32071418
Drug: Ruxolitinib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib therapy in both acute and chronic srGVHD
Trial: 32071614
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (control) for 4 months, followed by SSM intervention.
Trial: 32072161
Drug: Intravenous fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fish oil (FO) 1 g/kg/d
Trial: 32074275
Drug: Azacitidine (AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (AZA) at 75 mg/m2 subcutaneously or IV once daily on days 1 to 5 followed by HiDAC (3000 mg/m2) and mitoxantrone (30 mg/m2) once each on days 6 and 10.
Trial: 32074275
Drug: Azacitidine (AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (AZA) at 50 mg/m2 (dose-limiting toxicities occurred).
Trial: 32074275
Drug: Azacitidine (AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (AZA) at 37.5 mg/m2 (not specifically reported).
Trial: 32074665
Drug: Calcipotriol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) foam applied once daily for ≤4 weeks
Trial: 32074665
Drug: Calcipotriol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) foam
Trial: 32075470
Drug: Dupilumab, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 signaling, specific dosage and duration not mentioned.
Trial: 32075790
Drug: Macrolide antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrolide antibiotics during pregnancy (first trimester)
Trial: 32075790
Drug: Macrolide antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrolide antibiotics during pregnancy (any trimester)
Trial: 32075790
Drug: Penicillin antibiotics
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin antibiotics during pregnancy
Trial: 32076124
Drug: AZD3965 (mono-carboxylase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3965 (mono-carboxylase transporter 1 inhibitor)
Trial: 32076889
Drug: Dotinurad (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dotinurad (4 mg) with oxaprozin
Trial: 32076889
Drug: Dotinurad (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dotinurad (4 mg) alone
Trial: 32077361
Drug: Sequential ('primed')
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential ('primed') decitabine in combination with CLAG-M
Trial: 32077361
Drug: Concurrent decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent decitabine in combination with CLAG-M
Trial: 32077895
Drug: Trabectedin (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin (1.3 mg/m2 starting dose, 1.5 mg/m2 dose level +1, 1.1 mg/m2 dose level -1) plus radiotherapy (30 Gy, 3 Gy/d for 10 days)
Trial: 32077895
Drug: Trabectedin (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin (1.3 mg/m2 starting dose, 1.5 mg/m2 dose level +1, 1.1 mg/m2 dose level -1)
Trial: 32078124
Drug: Split first
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split first dose of intravenous daratumumab (16 mg/kg split into two 8 mg/kg doses on Days 1 and 2)
Trial: 32078124
Drug: Single first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single first dose of intravenous daratumumab (16 mg/kg)
Trial: 32078124
Drug: Split first
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split first dose of intravenous daratumumab
Trial: 32078124
Drug: Single first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single first dose of intravenous daratumumab
Trial: 32078813
Drug: Cabozantinib (adults
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (adults 60 mg, children <16 years 40 mg)
Trial: 32079476
Drug: Modifiable bleeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modifiable bleeding risk factors (heavy alcohol use, uncontrolled hypertension, concomitant treatment with antiplatelets, NSAIDs, or paracetamol)
Trial: 32079702
Drug: ctDNA analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ctDNA analysis after 2 cycles of chemotherapy (C2)
Trial: 32079709
Drug: PARP inhibitors
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP inhibitors (olaparib, niraparib, rucaparib)
Trial: 32083013
Drug: Adjuvant Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Immunotherapy
Trial: 32084409
Drug: Ad5-DS (adenovirus-mediated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-DS (adenovirus-mediated double-suicide gene therapy) injected into pancreatic mass with EUS-guided fine needles, combined with oral 5-fluorocytosine and valganciclovir, and standard dose of intravenous gemcitabine.
Trial: 32085891
Drug: Lurbinectedin monotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurbinectedin monotherapy, administered intravenously at 3.2 mg/m²
Trial: 32086343
Drug: Toripalimab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (3 mg/kg once every two weeks)
Trial: 32086361
Drug: Pharmacist-led intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led intervention using the Drug Burden Index (DBI) Calculator
Trial: 32086697
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy (double-scattered conformal proton therapy) to a mean dose of 54 GyRBE in 1.8 GyRBE/fraction (range 52.2-54 GyRBE)
Trial: 32086697
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy (double-scattered conformal proton therapy)
Trial: 32087152
Drug: Medication refills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication refills at week 4
Trial: 32087152
Drug: Medication refills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication refills at week 72
Trial: 32087715
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept (50 mg for 10-<25 kg, 87.5 mg for 25-<50 kg)
Trial: 32087715
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept (with/without methotrexate and/or low-dose corticosteroids)
Trial: 32087733
Drug: PCV +
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCV + PPV23 in all treatment groups
Trial: 32088180
Drug: Adjunctive strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive strategies (neuromuscular blockade, prone position, extracorporeal membrane oxygenation, inhaled vasodilators, high-frequency ventilation)
Trial: 32088180
Drug: Adjunctive strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive strategies
Trial: 32088322
Drug: GLS-6150 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLS-6150 (4 mg, 3 mg, or 6 mg/vaccination, administered 4 times at 4-week intervals, followed by a 6 mg boost at 24 weeks)
Trial: 32088879
Drug: Glycemia overtreatment
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycemia overtreatment (HbA1c < 6.5% with ≥ 2 oral antihyperglycemics or insulin)
Trial: 32088879
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure overtreatment (SBP < 120 mmHg or DBP < 65 mmHg with ≥ 2 drugs)
Trial: 32088879
Drug: Deintensification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deintensification of glycemia treatment
Trial: 32088879
Drug: Intensification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification of glycemia treatment
Trial: 32088879
Drug: Deintensification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deintensification of BP treatment
Trial: 32088879
Drug: Intensification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification of BP treatment
Trial: 32089047
Drug: Hyperoxia treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperoxia treatment, specific dosage and duration not mentioned
Trial: 32089164
Drug: CCR5 antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CCR5 antagonists
Trial: 32089640
Drug: Ganetespib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganetespib (200 mg/m) and Sirolimus (oral mTOR inhibitor)
Trial: 32089871
Drug: Panretinal photocoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panretinal photocoagulation (PRP) and/or intravitreal injections (IVIs) of anti-VEGF
Trial: 32091493
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 4 or 6 mg/kg every 8 hours by 1-hour intravenous infusion plus intravenous ampicillin and optional aminoglycoside for 48 hours-14 days
Trial: 32091493
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 6 mg/kg every 8 hours
Trial: 32091590
Drug: Atropine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.04 mg/kg intravenous)
Trial: 32092139
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg/d in combination with cytarabine/daunorubicin induction on days 1 to 7, followed by dasatinib 100 mg/d on days 6 to 26 for 4 courses, and then dasatinib 100 mg/d for 12 months after achieving complete remission.
Trial: 32092139
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg/d
Trial: 32093506
Drug: Noninvasive remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive remote monitoring using a disposable multisensor patch
Trial: 32093649
Drug: Gemcitabine/erlotinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/erlotinib treatment with skin rash
Trial: 32093649
Drug: Gemcitabine/erlotinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/erlotinib treatment without skin rash
Trial: 32093649
Drug: Gemcitabine/erlotinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/erlotinib treatment with skin rash grade ≥ 2
Trial: 32093649
Drug: Gemcitabine/erlotinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/erlotinib treatment in patients > 65 years
Trial: 32093649
Drug: Gemcitabine/erlotinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/erlotinib treatment
Trial: 32094063
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks in 6-week cycles
Trial: 32094925
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment for subretinal inflammation
Trial: 32313553
Drug: Ready-to-drink SPMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-drink SPMC oral solution
Trial: 32095161
Drug: Split-dose, low-volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose, low-volume sodium picosulfate, magnesium oxide, and citric acid powder for oral solution
Trial: 32095777
Drug: Single intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection of aflibercept
Trial: 32095919
Drug: 4 MBq/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 MBq/kg dosage group
Trial: 32095919
Drug: 2 MBq/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 MBq/kg dosage group
Trial: 39630397
Drug: Furosemide administration
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide administration
Trial: 32096654
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose monitoring system which wirelessly transmits results to compatible insulin pumps
Trial: 32097091
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg and bevacizumab 15 mg/kg given intravenously every 3 weeks (phase II)
Trial: 32097119
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (graded repetitive arm supplementary program; GRASP) with no supervision for 2 months.
Trial: 32098623
Drug: Oral Ty21a
RxNorm normalized name: Salmonella typhi Ty21a live antigen 2000000000 UNT [Vivotif]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ty21a (4 doses)
Trial: 32098874
Drug: Rituximab (RTX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (RTX), administered in a minimum of two to a maximum of three cycles, specific dosage and duration not detailed.
Trial: 32100175
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered via target controlled infusion (TCI) with EEG-derived bispectral index (BIS) monitoring.
Trial: 32100191
Drug: Continuous variable
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous variable of canned and cooked tomato consumption (64 g/day)
Trial: 32100191
Drug: 24-h dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-h dietary recall intake of 71 g/day canned and cooked tomato product
Trial: 32100192
Drug: Gla-300 (Glargine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gla-300 (Glargine 300 U/mL)
Trial: 32100192
Drug: IDeg-100 (Degludec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDeg-100 (Degludec 100 U/mL)